News | April 10, 2024

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) – Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson &...

News | March 11, 2024

Merck Completes Acquisition of Harpoon Therapeutics, Inc. Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager RAHWAY, N.J.–(BUSINESS...

News | October 26, 2023

Bluesight Appoints Jason Vander Meer as Chief Product Officer to Expand Medication Intelligence Suite New leader of product strategy and development to drive innovation, support company’s growth plans ALEXANDRIA, Va., Oct. 26, 2023 — Bluesight, the leader in...

News | October 23, 2023

HARPOON THERAPEUTICS ANNOUNCES UP TO $150 MILLION PRIVATE PLACEMENT SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers,...

News | September 20, 2023

Kalderos names veteran healthcare leader Angie Franks as new CEORedefining how the business of healthcare performs.™ (PRNewsfoto/Kalderos) Experienced chief executive brings growth mindset,strong vision to Drug Discount Management solution leader CHICAGO, Sept. 20,...

News | September 23, 2023

Kalderos Adds Powerful Features to Commercial Drug Discount Monitoring SolutionRedefining how the business of healthcare performs.™ (PRNewsfoto/Kalderos) Drug Discount Management Leader Delivers New Tools to Tackle Billions in Overpaid Commercial Rebates CHICAGO,...